- Home
- LIDR vs AVTX Comparison
LIDR vs AVTX Comparison
Compare LIDR & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- AVTX
- Stock Information
- Founded
- LIDR 2013
- AVTX 2011
- Country
- LIDR United States
- AVTX United States
- Employees
- LIDR N/A
- AVTX N/A
- Industry
- LIDR Auto Parts:O.E.M.
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- LIDR Consumer Discretionary
- AVTX Health Care
- Exchange
- LIDR Nasdaq
- AVTX Nasdaq
- Market Cap
- LIDR 108.6M
- AVTX 126.9M
- IPO Year
- LIDR N/A
- AVTX 2015
- Fundamental
- Price
- LIDR $2.82
- AVTX $9.29
- Analyst Decision
- LIDR
- AVTX Strong Buy
- Analyst Count
- LIDR 0
- AVTX 8
- Target Price
- LIDR N/A
- AVTX $31.00
- AVG Volume (30 Days)
- LIDR 8.4M
- AVTX 306.4K
- Earning Date
- LIDR 07-31-2025
- AVTX 08-07-2025
- Dividend Yield
- LIDR N/A
- AVTX N/A
- EPS Growth
- LIDR N/A
- AVTX N/A
- EPS
- LIDR N/A
- AVTX N/A
- Revenue
- LIDR $236,000.00
- AVTX $441,000.00
- Revenue This Year
- LIDR $2,677.23
- AVTX N/A
- Revenue Next Year
- LIDR $409.09
- AVTX N/A
- P/E Ratio
- LIDR N/A
- AVTX N/A
- Revenue Growth
- LIDR N/A
- AVTX N/A
- 52 Week Low
- LIDR $0.49
- AVTX $3.39
- 52 Week High
- LIDR $6.44
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- LIDR 53.26
- AVTX 62.48
- Support Level
- LIDR $2.37
- AVTX $9.16
- Resistance Level
- LIDR $3.49
- AVTX $9.84
- Average True Range (ATR)
- LIDR 0.32
- AVTX 0.68
- MACD
- LIDR -0.04
- AVTX -0.10
- Stochastic Oscillator
- LIDR 40.18
- AVTX 50.09
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).